id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-3865-0007,FDA,FDA-2024-E-3865,Determination of Regulatory Review Period for Purposes of Patent Extension; OJEMDA,Notice,Determinations,2025-12-29T05:00:00Z,2025,12,2025-12-29T05:00:00Z,2026-02-28T04:59:59Z,2025-12-29T19:57:00Z,2025-23867,0,0,09000064b910a301
FDA-2024-E-3865-0006,FDA,FDA-2024-E-3865,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-08-19T04:00:00Z,2025,8,2025-08-19T04:00:00Z,,2025-08-19T22:20:43Z,,0,0,09000064b8f0859c
FDA-2024-E-3865-0005,FDA,FDA-2024-E-3865,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-07-15T04:00:00Z,2025,7,2025-07-15T04:00:00Z,,2025-07-15T19:46:05Z,,0,0,09000064b8e6f0f1
FDA-2024-E-3865-0004,FDA,FDA-2024-E-3865,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2025-06-30T04:00:00Z,2025,6,2025-06-30T04:00:00Z,,2025-06-30T20:41:57Z,,0,0,09000064b8e4299d
FDA-2024-E-3865-0003,FDA,FDA-2024-E-3865,"Patent Extension Application from Day One Biopharmaceuticals, Inc. (on behalf of Viracta Therapeutics, Inc.) for NDA 218033",Other,Application,2024-08-19T04:00:00Z,2024,8,2024-08-19T04:00:00Z,,2024-08-19T12:31:40Z,,0,0,090000648664423a
FDA-2024-E-3865-0001,FDA,FDA-2024-E-3865,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-08-19T04:00:00Z,2024,8,2024-08-19T04:00:00Z,,2024-08-19T12:31:20Z,,0,0,0900006486644236
FDA-2024-E-3865-0002,FDA,FDA-2024-E-3865,"Patent Extension Application from Day One Biopharmaceuticals, Inc. (on behalf of Viracta Therapeutics, Inc.)  for NDA 217700",Other,Application,2024-08-19T04:00:00Z,2024,8,2024-08-19T04:00:00Z,,2024-08-19T12:31:30Z,,0,0,0900006486644238